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Surveillance of rubella in England and Wales has in-
cluded immunoglobulin M testing of oral (crevicular) ﬂ  uid 
from reported case-patients since 1994. The need for 
laboratory conﬁ   rmation to monitor rubella elimination is 
emphasized by poor sensitivity (51%, 95% conﬁ  dence in-
terval 48.9%–54.0%) and speciﬁ  city (55%, 95% conﬁ  dence 
interval 53.7%–55.6%) of the clinical case deﬁ  nition. During 
1999–2008, oral ﬂ  uid from 11,709 (84%) of 13,952 reported 
case-patients was tested; 143 (1.0%) cases were conﬁ  rmed 
and 11,566 (99%) were discarded (annual investigation 
and discard rate of clinically suspected rubella cases was 
2,208/100,000 population). Incidence of conﬁ  rmed rubella 
increased from 0.50 to 0.77/1 million population when oral 
ﬂ   uid testing was included. Oral ﬂ   uid tests conﬁ  rmed  that 
cases were more likely to be in older, unvaccinated men. 
Testing of oral ﬂ   uid has improved ascertainment of con-
ﬁ  rmed rubella in children and men and provided additional 
information for assessing UK progress toward the World 
Health Organization elimination goal.
I
n 1970, rubella vaccination was introduced in the United 
Kingdom for prepubertal girls and nonimmune women 
of childbearing age to protect them from the risks for ru-
bella during pregnancy. Although this selective vaccination 
policy effectively reduced the number of cases of congeni-
tal rubella syndrome (CRS) and terminations of pregnancy, 
rubella during pregnancy continued to occur (1). In 1988, 
measles, mumps, and rubella (MMR) vaccine was intro-
duced for universal vaccination at 13–15 months of age 
with the goal of eliminating circulating rubella.
A considerable decrease in rubella in young children 
followed, but in 1993, clinically diagnosed and laboratory-
conﬁ  rmed rubella increased; the increase occurred predom-
inantly in older men who had previously not been offered 
a rubella-containing vaccine (2). Therefore, in November 
1994, rubella vaccine was included in a school catch-up 
campaign to prevent a predicted measles epidemic (3). Ap-
proximately 92% of children 5–16 years of age received 
combined measles–rubella vaccine. In 1996, to maintain 
measles control, a second dose of MMR was recommended 
for children 5 years of age.
For any disease in the elimination phase, accurate 
surveillance is necessary to identify reservoirs of infec-
tion and susceptible groups (2). In 2005, the World Health 
Organization (WHO) European Region adopted a resolu-
tion to eliminate indigenous rubella by 2010 (elimination 
goal of conﬁ  rmed rubella incidence <1 per 1 million popu-
lation) (4). WHO has developed a clinical case deﬁ  nition 
for rubella (5), but identiﬁ  cation of cases based on clinical 
suspicion alone becomes less reliable as disease incidence 
decreases. Therefore, for countries trying to eliminate ru-
bella, laboratory conﬁ  rmation of all suspected cases is rec-
ommended (4).
Before 1994, surveillance of laboratory-conﬁ  rmed ru-
bella in England and Wales was based mainly on detection 
of immunoglobulin (Ig) M against rubella in serum. How-
ever, because rubella infection is usually mild, physicians 
are reluctant to obtain blood samples for serum conﬁ  rma-
tion, especially from young children. There is also some re-
luctance to obtain serum from men because the diagnosis is 
not of major clinical signiﬁ  cance. Oral or crevicular ﬂ  uid is 
a noninvasively obtained clinical specimen that is likely to 
be more acceptable, especially for children, and is safe and 
easy to obtain (6–9). Transudates from the capillary bed 
situated beneath the margin between the tooth and gum are 
obtained by rubbing an absorptive device between the gum 
and the cheek. These samples, which are distinguishable 
Oral Fluid Testing during 10 Years 
of Rubella Elimination, England 
and Wales 
Gayatri Manikkavasagan, Antoaneta Bukasa, Kevin E. Brown, Bernard J. Cohen, and Mary E. Ramsay
RESEARCH
1532  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 10, October 2010
Author afﬁ  liation: Health Protection Agency Centre for Infections, 
London, UK
DOI: 10.3201/eid1610.100560Oral Fluid Testing and Rubella, England and Wales
from saliva samples, contain mucosal cells that enable de-
tection of the rubella virus by PCR. Methods for obtaining, 
extracting, and storing oral ﬂ  uid samples are well estab-
lished (7,10–13). Detection of rubella IgM in oral ﬂ  uid has 
been validated and shown to be ≈90% sensitive and 99% 
speciﬁ  c compared with detection in serum (2). Samples are 
also suitable for genome detection (14,15). Therefore, since 
late 1994, the enhanced surveillance program in England 
and Wales has relied on oral ﬂ  uid testing to provide labora-
tory conﬁ  rmation for clinically diagnosed cases of measles, 
mumps, and rubella (however, serum testing is still recom-
mended for conﬁ  rmation of infection during pregnancy).
An additional increase in rubella incidence occurred 
during 1995–1998. Reports of rubella peaked in 1996 (a 
total of 9,081 clinically diagnosed cases were reported) 
(16). This situation offered an opportunity to evaluate the 
sensitivity and speciﬁ  city of the WHO clinical case deﬁ  ni-
tion for rubella. In addition, we describe the added value of 
oral ﬂ  uid testing during the subsequent 10 years of rubella 
elimination (1999–2008).
Methods
Since 1988, physicians in England and Wales have 
been required by law to report clinically suspected cases 
of rubella to the proper ofﬁ  cer at the local health authority 
(usually a public health consultant in a Health Protection 
Unit [HPU]). Since late 1994, when a report is received, the 
HPU sends an oral ﬂ  uid kit to the primary-care physician or 
patient for conﬁ  rmatory testing. The kit is then returned by 
prepaid envelope to the Virus Reference Department at the 
Health Protection Agency Centre for Infections, for analy-
sis. A request form contains vaccination history and, until 
July 2003, some brief clinical features (presence of a rash, 
fever, conjunctivitis, cough, and lymphadenopathy [type not 
speciﬁ  ed]). Oral ﬂ  uid testing was also used to test cases that 
were not formally reported as part of outbreaks in 3 univer-
sities associated with imported virus from Greece in 1999 
(17). A similar process is used for measles (and mumps) 
(18,19). If there is a strong clinical or epidemiologic suspi-
cion of rubella in samples tested for measles and for measles 
in samples tested for rubella, dual testing is performed.
Oral (crevicular) ﬂ  uid specimens, obtained by wiping 
a specially designed sponge swab (oral test kit [Oracol; 
Malvern Medical Developments, Worcester, UK]) around 
the gum margins, were tested for rubella-speciﬁ  c IgM ini-
tially by using a solid-phase IgM–antibody capture radio-
immunoassay (20). After 2002, an in-house assay for ru-
bella IgG was introduced (21), and after 2003, all samples 
taken within 1 week after symptom onset that were nega-
tive for rubella IgM and rubella IgG were tested by reverse 
transcription–PCR for rubella virus (14). In 2006, the ru-
bella solid-phase IgM–antibody capture radioimmunoassay 
was replaced by a commercial enzyme immunoassay (22).
Results of testing were sent to the reporting physician, 
and copies were sent to the relevant HPU. Conﬁ  rmed cases 
were deﬁ  ned as samples positive for rubella-speciﬁ  c IgM 
in oral ﬂ  uid or detection of rubella virus genome by PCR 
in persons without a history of receipt of rubella vaccine 
in the previous 6 weeks. These cases were reconciled with 
conﬁ  rmed rubella infections (positive for rubella IgM in se-
rum) reported to the Health Protection Agency Centre for 
Infections, from laboratories in England and Wales, and 
duplicates are removed. Since 1999, residual samples from 
cases reported by local laboratories are requested to be sent 
to the national reference laboratory for conﬁ  rmation by an 
alternative IgM assay (with or without avidity testing) (23). 
Cases with negative results for the second IgM test or with 
high avidity are then excluded from the conﬁ  rmed total. 
Further details (including travel and contact history) are re-
quested, and vaccination status is checked for all conﬁ  rmed 
case-patients.
Data obtained during January 1995–July 2003 were 
analyzed to estimate the sensitivity and speciﬁ  city of a 
clinical case deﬁ  nition. The WHO deﬁ  nition of a case of 
rubella is a generalized maculopapular rash and fever and 
arthralgia/arthritis or cervical, suboccipital, or postauricu-
lar lymphadenopathy (5). Because information for arthritis 
was not routinely obtained, the accuracy of a modiﬁ  ed case 
deﬁ  nition based on rash, fever, and lymphadenopathy was 
calculated against the standard of presence or absence of 
rubella-speciﬁ  c IgM in an oral ﬂ  uid sample. The sensitivi-
ty, speciﬁ  city, and positive predictive value were compared 
by patient age, sex, and year of report.
Data obtained during January 1999–December 2008 
from 3 sources (clinically reported cases, conﬁ  rmation in 
oral ﬂ  uid samples, and laboratory reports) were then com-
pared with respect to age, sex, vaccination status, and re-
gion. Rates were calculated by using 2001 population esti-
mates from the Ofﬁ  ce for National Statistics. The incidence 
rate for cases conﬁ  rmed positive by oral ﬂ  uid was adjusted 
for the proportion of reported cases tested in each region 
and compared with the rate from laboratory reports alone. 
All analyses were conducted by using Stata/SE version 9.2 
(StataCorp LP, College Station, TX, USA). Proportions 
were compared by using the χ2 test.
Results
Accuracy of Clinical Case Deﬁ  nition
During January 1995–July 2003, of 29,825 reported 
case-patients, oral ﬂ  uid from 17,042 (57%) was tested for 
IgM; complete clinical information was obtained for 12,220 
(72%) patients who submitted oral ﬂ   uid samples. The 
overall sensitivity of the clinical case deﬁ  nition of macu-
lopapular rash and fever and lymphadenopathy was 51% 
(95% conﬁ  dence interval 48.9%–54.0%) and the speciﬁ  c-
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ity was 55% (95% conﬁ  dence interval 53.7%–55.6%). The 
sensitivity and speciﬁ  city of this case deﬁ  nition did not 
show signiﬁ  cant variation by age, sex, and year of report-
ing (Table 1). However, the positive predictive value was 
signiﬁ  cantly higher for persons >15 years of age (71% for 
persons 15–24 years of age compared with 1% for persons 
5–9 years of age), for men (21% compared with 5% for 
women), and during the 1995–1998 epidemic period (20% 
compared with 1% in January 1999–July 2003).
Enhanced Surveillance, 1999–2008
During 1999–2008, a total of 13,952 clinically suspected 
rubella cases were reported, and the number of cases per year 
(1,000–2,000) remained stable (Figure). Oral ﬂ  uid was tested 
for 11,709 (84%) case-patients; 143 (1.0%) positive results 
were conﬁ   rmed, and 11,566 (99%) of the results were discarded 
(Table 2) This ﬁ  nding is equivalent to an annual investigation 
and discard rate of 2,208 clinically suspected rubella cases per 
100,000 population. Over the 10-year period, the proportion 
of conﬁ  rmed cases for which oral ﬂ  uid was tested increased 
from 39% (49/127) in 1999 to 49% (16/33) in 2008. The 
annual number of cases conﬁ  rmed positive by oral ﬂ  uid test 
remained <30 (Figure). The proportion of cases with a con-
ﬁ  rmatory test result has decreased since 1999 and remained 
<2%, except for a temporary increase in 2007 to 2.8%. Dur-
ing the 10-year period, 263 additional cases were conﬁ  rmed 
by serum testing, resulting in 406 conﬁ  rmed cases compared 
with 13,952 clinically diagnosed cases. Because laboratories 
in England and Wales report only cases that were conﬁ  rmed 
positive, the number of additional cases tested and results 
discarded after serum testing alone is not known.
The age and sex distribution of case-patients reported 
from each surveillance source differed markedly (Table 2). 
The proportion of reported cases for which oral ﬂ  uid was test-
ed was higher for children <15 years of age (10,763/12,588 
[86%]) than for persons >15 years (717/1,242 [58%]). 
However, cases in children <15 years of age were signiﬁ  -
cantly less likely to be conﬁ  rmed positive by oral ﬂ  uid test-
ing than were cases in persons >15 years of age (54/10,763 
[0.5%] vs. 89/717 [12%]; p = 0.0001). Adults represented 
the largest proportion of all serum-conﬁ  rmed case-patients 
during the 10-year period. However, a higher proportion of 
cases for which oral ﬂ  uid was tested were in children <15 
years of age than cases conﬁ  rmed by serum testing (54/89 
[61%] vs. 52/209 [25%], respectively; p = 0.0001).
Reports of rubella showed an approximately equal sex 
distribution among persons <15 years of age but showed 
a slight preponderance of female patients among adults 
(Table 2). The proportion of reported cases for which oral 
ﬂ  uid was tested did not differ by sex (6,084/7,211 [84%] 
male patients and 5,521/6,644 [83%] female patients). The 
proportion of cases conﬁ  rmed positive by oral ﬂ  uid testing 
was similar for boys and girls <15 years of age but sig-
niﬁ  cantly higher for men than for women (63/265 [24%] 
vs. 26/442 [5.9%]; p = 0.0001). Cases conﬁ  rmed by serum 
testing showed an equal sex distribution, whereas cases 
conﬁ  rmed by oral ﬂ  uid testing showed a predominance 
of male patients (125/253 [49%] and 92/141 [65%] male 
patients among serum-conﬁ  rmed and oral ﬂ  uid–conﬁ  rmed 
cases, respectively; p = 0.002).
Data sources also differed with respect to vaccina-
tion status. The proportion of reported cases that could 
be conﬁ  rmed as rubella was almost 7× higher for unvac-
cinated than for vaccinated persons (128/6,543 [2.0%] and 
15/5,122 [0.3%], respectively; p<0.0002). However, the 
absolute difference varied with age. Although a small but 
signiﬁ  cant difference occurred between unvaccinated and 
vaccinated children <5 years of age (40/5,515 [0.7%] and 
5/3,007 [0.2%], respectively; p = 0.0007), the difference 
was much larger in persons 15–24 years of age (46/150 
[31%] and 2/171 [1.2%], respectively; p<0.0001).
Regional distribution varied by data source (Table 3). 
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Table 1. Accuracy of World Health Organization–modified clinical case definition for rubella, England and Wales, 1999–2008* 
Characteristic
Sensitivity Specificity Positive predictive value
No. positive/ 
no. tested  % (95% CI) 
No. positive/ 
no. tested  % (95% CI) 
No. positive/ 
no. tested  % (95% CI) 
Age, y
  <1 22/37 59.5 (43.6–75.3) 1,467/2,804 52.3 (50.5–54.2) 22/1,359 1.6 (1.0–2.3)
 1–4 34/75 45.3 (34.1–56.6) 2,303/4,522 50.9 (49.5–52.4) 34/2,253 1.5 (1.0–2.0)
 5–9 7/11 63.6 (35.2–92.1) 1,006/1,640 61.3 (59.0–63.7) 7/641 1.1 (0.3–1.9)
 10–14 10/32 31.3 (15.2–47.3) 298/426 70.0 (65.6–74.3) 10/138 7.2 (2.9–11.6)
 15–24 433/871 49.7 (46.4–53.0) 281/462 60.8 (56.4–65.3) 433/614 70.5 (66.9–74.1)
 > 25 256/455 56.3 (51.7–60.8) 257/439 58.5 (53.9–63.2) 256/438 58.4 (53.8–63.1)
Sex
  M 649/1,278 50.8 (48.0–53.5) 2,877/5,326 54.0 (52.7–55.4) 649/3,098 20.9 (19.5–22.4)
 F 112/202 55.4 (48.6–62.3) 2,744/4,954 55.3 (54.0–56.8) 112/2,322 4.8 (3.95–5.7)
Year of report
  1995 Jan–1998 Dec 743/1,435 51.8 (49.2–54.4) 3,630/6,677 54.4 (53.2–55.6) 743/3,790 19.6 (18.3–20.9)
  1999 Jan–2003 Jul 18/46 39.1 (25.0–53.2) 1,983/3,616 54.8 (53.2–56.5) 18/1,651 1.1 (0.6–1.6)
*CI, confidence interval. Oral Fluid Testing and Rubella, England and Wales
The annual incidence based on reported cases was high-
est in the North East region and lowest in Wales, whereas 
the annual incidence based on laboratory reports of serum 
conﬁ  rmation was highest in London. Incidence based on 
oral ﬂ  uid test results also differed, even after adjustment 
for the proportion of reported cases tested. The estimated 
overall incidence of conﬁ  rmed rubella increased by 54% 
(from 0.50 cases/1 million population to 0.77 cases/1 mil-
lion population) when data for oral ﬂ  uid testing were in-
cluded. Oral ﬂ  uid data also changed the ranking of regions; 
the Eastern region overtook London in reporting the high-
est overall incidence. Although the West Midlands and 
Yorkshire and Humberside regions reported the lowest in-
cidence on the basis of serum testing alone, after oral ﬂ  uid 
testing was included, the East Midlands region reported the 
lowest overall incidence.
Discussion
Before vaccination was introduced, epidemics of ru-
bella occurred regularly and caused mild rash illness, pre-
dominantly in children. In 1970, introduction of a selective 
vaccination policy in the United Kingdom aimed to reduce 
the risk for infection in early pregnancy and the risk for 
fetal death and CRS. Despite the success of the selective 
policy, MMR was adopted into the routine childhood vac-
cination schedule to eliminate circulating rubella and to 
further reduce the risk for CRS.
Since 1988, a clinical diagnosis of rubella has been re-
portable by registered medical practitioners in England and 
Wales under the statutory Notiﬁ  cation of Infectious Dis-
eases; there is no case deﬁ  nition. When an infection is com-
monly occurring in an area, the positive predictive value of 
a clinical diagnosis may be sufﬁ  cient for accurate surveil-
lance (24). However, because rubella has become less com-
mon, an increasing proportion of reported cases are likely 
to be caused by other infections that have similar clinical 
manifestations. The rash of rubella may be temporary and 
can resemble the rash caused by other viruses. For example, 
infection with parvovirus B19, human herpesvirus 6 (roseo-
la infantum), and human herpesvirus 7 all involve rash and 
fever and may be misdiagnosed as rubella (25,26).
We have conﬁ  rmed the low sensitivity and speciﬁ  c-
ity of the clinical case deﬁ  nition and that this deﬁ  nition is 
not affected by age, sex, and period of reporting. Despite 
some missing clinical information and the absence of in-
formation about arthralgia, this ﬁ  nding suggests that the 
WHO clinical case deﬁ  nition is not sufﬁ  ciently accurate 
for surveillance in the postvaccine era. This ﬁ  nding also 
emphasizes the need to have laboratory conﬁ  rmation of 
all clinically diagnosed cases to accurately monitor ru-
bella elimination (27).
Over the 10-year period of elimination, only ≈1 of 100 
persons reported with clinically diagnosed rubella and who 
underwent oral ﬂ  uid testing had conﬁ  rmed cases. In ad-
dition, reported cases differed from laboratory-conﬁ  rmed 
cases with respect to patient age, sex, vaccination status, 
and geographic distribution. We have therefore shown that 
surveillance based only on clinical reports would substan-
tially overestimate the true incidence of rubella, particu-
larly in children, and therefore give a misleading epidemio-
logic picture. Furthermore, we have shown that testing of 
oral ﬂ  uid is acceptable in the United Kingdom and can be 
used to augment routine serologic diagnosis. Approximate-
ly one third of conﬁ  rmed rubella cases were diagnosed by 
testing of oral ﬂ  uid, which improved ascertainment of con-
ﬁ  rmed infections in children and men. In addition, by using 
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Figure. Number of rubella cases reported, number of oral (crevicular) 
ﬂ  uid tests performed, and proportion of reported cases conﬁ  rmed 
by oral ﬂ  uid testing, England and Wales, 1999–2008.
Table 2. Reported and confirmed rubella cases in enhanced surveillance program, England and Wales, 1999–2008* 
Age, y 
Total no. reports 
No. cases confirmed by oral 
(crevicular) fluid testing 
No. additional cases confirmed by 
serum testing 
M F UNK Total no. (%) M   F UNK Total no. (%) M  F UNK Total no. (%)
<1 1,823  1,674  23 3,520 (25.0) 10 10 1 21 (15.0)  4 2 1 7 (2.7) 
1–4 3,406  2,882  37 6,325 (45.0) 14 9 1 24 (17.0)  19 10 1 30 (11.0) 
5–9 1,083  1,005  14 2,102 (15.0) 2 3 0 5 (3.5)  2 2 0 4 (1.5) 
10–14  339 298 4 641 (4.6)  3 1 0 4 (0.3)  7 3 1 11 (4.2) 
>15 506 729 7 1,242 (8.9)  63 26 0 89 (62.0)  93 109 7 209 (79.0) 
UNK 54 56 12 122 0 0 0 0   0 2 0 2
Total no. 
(%) 
7,211
(52.0) 
6,644
(48.0) 
97 13,952 92
(64.0)
49
(34.0)
2 143 125
(48.0) 
128
(48.0) 
10 263
*UNK, unknown. RESEARCH
PCR, we obtained genotype information on 12 samples that 
would have otherwise not been available.
Currently, there is only 1 commercial assay for testing 
rubella IgM in oral ﬂ  uid, and this assay does not have an 
In Vitro Diagnostics license, thus limiting its use in some 
countries. However, in many regions, WHO is evaluating 
this assay as a tool for surveillance of infection (28; K. 
Brown, pers. comm.) Although the UK system relies upon 
a well-organized postal service, alternative approaches for 
delivering and receiving specimens directly from the pa-
tient’s home or family practice may be required in other 
countries considering the use of oral ﬂ  uid.
In addition to antibody testing, oral ﬂ  uid can be used 
for rubella RNA detection in samples obtained early during 
infection (13) and for genotyping and molecular epidemio-
logic studies (14,15). Tests for detecting rubella-speciﬁ  c 
IgM and RNA in oral ﬂ  uid samples are also suitable for 
conﬁ  rming a diagnosis of CRS (11). The same system is 
also being used to monitor measles and mumps incidence 
and to inform MMR vaccine policy in England and Wales 
(18,19,29,30).
Oral ﬂ  uid testing can also be used to evaluate the com-
pleteness of rubella surveillance. Since 1999, the number 
of reports of rubella and oral ﬂ  uid tests performed annually 
has remained constant, and the proportion of cases tested 
has remained high. When combined with a low rate of con-
ﬁ  rmation, including cases diagnosed as clinical rubella, in a 
country with free universal access to high-quality primary-
care physicians, this ﬁ  nding suggests that surveillance of 
conﬁ  rmed rubella is nearly complete in England and Wales. 
Despite this suggestion, annual incidence of conﬁ  rmed ru-
bella remains <1 per 1 million population, which is the goal 
for elimination (4).
In recently published surveillance guidelines, WHO 
has recommended IgM detection, which can be performed 
with serum and oral ﬂ  uid (31). These guidelines also de-
scribe performance indicators to assess the quality of na-
tional surveillance systems in the elimination phase. These 
indicators include a laboratory investigation rate (propor-
tion of clinically suspected cases with adequate specimens 
for IgM testing) >80% and a detection rate for the number 
of clinically suspected rubella cases investigated and dis-
carded by laboratory testing >2/100,000 population/year. 
Data from the enhanced surveillance program show that for 
≈84% of reported cases, oral ﬂ  uid was tested, and results for 
2,208 clinically suspected rubella cases per 100,000 popu-
lation were investigated and discarded. This high discard 
rate would be feasible only with noninvasive testing and 
contributes to the high quality of the UK enhanced surveil-
lance program. Information about the low rate of rubella 
supplements surveillance that conﬁ  rms that CRS incidence 
in the United Kingdom was 0.14/100,000 live-born infants 
in 2007 (32), which was far below the WHO elimination 
goal of 1/100,000 live-born infants (4).
We conﬁ  rmed that a clinical case deﬁ  nition alone is 
not sufﬁ  ciently speciﬁ  c for surveillance of rubella in the 
elimination era and that laboratory conﬁ  rmation by testing 
serum samples is biased and incomplete. Since 1999, a sub-
stantial proportion of conﬁ  rmed cases of rubella identiﬁ  ed 
through the enhanced surveillance scheme have occurred in 
unvaccinated men. With the availability of oral ﬂ  uid test-
ing, a high number and high proportion of suspected cases 
have been tested. However, numbers of conﬁ  rmed rubella 
cases in children remain low, which is consistent with high 
levels of vaccine coverage and low levels of susceptibil-
ity in this younger age group (33). The enhanced oral ﬂ  uid 
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Table 3. Regional variation in rubella reports by oral (crevicular) fluid testing and confirmed cases from oral fluid and serum, England  
and Wales, 1999–2008 
Region 
No.
reported 
cases 
Incidence
of reported 
cases* 
No. oral fluid 
tests (% total 
reports) 
No. cases 
confirmed by 
oral fluid testing
No. cases 
confirmed by 
serum testing
Annual incidence of confirmed cases*
Confirmed by oral 
fluid testing† 
Confirmed by 
serum testing  Total 
East Midlands  1,336  319 1,065 (80)  3 9 0.09 0.21 0.29
Eastern 1,212 224 1,232  (102)‡  44 32 0.80 0.59 1.41
London 1,653  226 1,452  (88)  32 67 0.67 0.92 1.35
North East  840 331 574 (68)  0 12 0.00 0.47 0.47
North West  1,662  245 1,505 (91)  12 13 0.25 0.19 0.37
South East  2,363  295 2,350 (99)  18 48 0.34 0.60 0.82
South West  1,109  224 857 (77)  13 40 0.31 0.81 1.07
West Midlands  1,235  234 821 (66)  12 10 0.33 0.19 0.42
Wales 639 220 518 (81) 1 10 0.02 0.34 0.38
Yorkshire and 
Humberside 
1,903 382 1,260  (66)  7 22 0.20 0.44 0.58
Not specified 75 1 0
Total 13,952 266 11,709 (84)  143 263 0.31 0.50 0.77
*Incidence per 1 million population. Annual incidence calculated by using 2001 census population figures. 
†Adjusted for proportion of cases tested. 
‡Several oral fluid tests were conducted for cases that were not formally reported during university outbreaks in 3 regions in 1999, including the South  
West, Eastern, and North West regions (17).Oral Fluid Testing and Rubella, England and Wales
surveillance system has proven valuable for accurately as-
sessing progress toward achieving the WHO goal of elimi-
nating circulating rubella and CRS from the population of 
England and Wales.
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